Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jonathan A, Labuhn"'
Autor:
Philip J. Almeter, James T. Isaacs, Aaron N. Hunter, Bradley S. Henderson, Thomas Platt, Billie J. Mitchell, David Do, Alyssa B. Brainard, Joshua E. Brown, Rachael M. Stone, Bao-Han Nguyen, Matthew F. Warren, Smaran A. Bhaktawara, Megan N. Bossle, Lindsey M. Long, Stephanie P. Zapata, Cinnamon R. Larkin, Thomas A. Lyman, Seth A. Larkin, Jonathan A. Labuhn, Jeffrey W. Reynolds, Erin E. Schuler, Ryan W. Naseman, Gary L. Johnson, Robert A. Lodder
Publikováno v:
Journal of Pharmaceutical Innovation. 17:269-282
Since the US Food and Drug Administration (FDA) began monitoring the quality of pharmaceutical manufacturing by enforcing current good manufacturing practices roughly 60 years ago, forces related to the global economy have changed, rendering the task
Autor:
Philip J, Almeter, Wesley R, Butler, Jeffrey W, Reynolds, Deborah L, Duckworth, Jonathan A, Labuhn, Mark D, Birdwhistell
Publikováno v:
American Journal of Health-System Pharmacy. 79:1607-1611
Publikováno v:
Anesthesia & Analgesia. 127:1414-1420
BACKGROUND:The purpose of the US Food and Drug Administration’s Marketed Unapproved Drugs Initiative is to decrease marketing of older unapproved medications. The administration has recently extended its rulings by including sterile injectable drug
Publikováno v:
Anesthesia & Analgesia. 128:e55-e56
Autor:
Jonathan A. Labuhn, Christopher McLaughlin, Philip J. Almeter, Benjamin D. Turner, Philip Fields
Publikováno v:
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 74(15)
Purpose A successful supply chain optimization project that leveraged technology, engineering principles, and a technician workflow redesign in the setting of a growing health system is described. Summary With continued rises in medication costs, med